KRYS Krystal Biotech, Inc.

NEUTRAL Impact: 2/10 Insider Cluster (2 insiders)
Horizon days Filed Jun 5, 2026 Processed 15d 9h ago
Insider cluster: 2 insiders, $192K total
Latest settled — T+5d
KRYS ▲ +7.62% at T+5d
NEUTRAL call ✓ call won +7.62% · α vs SPY +5.51% · entry $301.76 → $324.75
Next anchor: T+20d in 15d
Last close $348.06 (close Jun 18) · +15.34% from $301.76 entry
Entry anchored
Jun 5, 2026
via day open
T+1d
+2.65%
call +2.65% · α +2.94%
$309.75
settled 13d ago
T+5d
+7.62%
call +7.62% · α +5.51%
$324.75
settled 9d ago
T+20d
call — · α —
in 15d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

President and CEO Krishnan Krish S and President of R&D Krishnan Suma each sold 320 shares of Krystal Biotech on June 4, 2026, for a combined $192K. The sales are tiny relative to the $9.1B market cap (0.002%), are identical in size and price, and likely reflect routine tax-related or 10b5-1 plan activity rather than a bearish signal. The cluster is not material enough to change the fundamental outlook.

Key Financial Metrics

Direction
selling
Total Value
$192.0K
Insiders
2

Actionable Insight

The insider sales are too small to warrant a trading response. Monitor for any larger open-market sales or changes in 10b5-1 plans. The company's strong analyst consensus (89% bullish) and positive historical performance on prior reports suggest the fundamental story remains intact.

Key Facts

  • Two insiders (CEO and President of R&D) each sold 320 shares at $300.75 on June 4, 2026.
  • Total sale value is $192K, representing ~0.002% of the $9.1B market cap.
  • Identical share counts and price suggest coordinated or plan-driven sales, not opportunistic selling.
  • No open-market purchases in the cluster; no other material insider activity in the prior 30 days.

Financial Impact

Trivial — $192K in sales vs. $9.1B market cap (0.002%). No material financial impact.

dilution

Risk Factors

  • Insider sales could increase if management is diversifying ahead of a catalyst event (e.g., pipeline readout).
  • No purchases in the cluster — lack of insider buying may indicate management sees limited near-term upside.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (18 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KRYS-1780699267801
9 reports for KRYS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+5▲ +17.06%May 16, 2026
Filters
Rows
Reports for KRYS — sortable, filterable
Type Now
Jun 16, 2026
5d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$249.39 $291.93▲ +17.06%▲ +16.77%$348.06 (+39.56%)
Jun 5, 2026
15d ago
Insider Cluster
NEUTRAL ★ 2/10
$301.76 $324.75▲ +7.62%▲ +5.51%$348.06 (+15.34%)
May 16, 2026
5w ago
ANALYST-UPGRADE
BULLISH ★ 5/10
$249.39 $291.93▲ +17.06%▲ +16.79%$348.06 (+39.56%)
May 4, 2026
6w ago
Press Release
BULLISH ★ 6/10
$286.95 $312.88▲ +9.04%▲ +6.10%$348.06 (+21.30%)
Apr 21, 2026
8w ago
Press Release
NEUTRAL ★ 3/10
$272.66 $269.27▼ −1.24%▼ −2.33%$348.06 (+27.65%)
Apr 16, 2026
9w ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$274.21 $272.52▼ −0.62%▼ −1.17%$348.06 (+26.93%)
Apr 3, 2026
11w ago
DEFA14A
NEUTRAL ★ 2/10
$261.80 $267.41▲ +2.14%▼ −1.99%$348.06 (+32.95%)
Feb 27, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$275.64 $253.69▼ −7.96%▼ −5.98%$348.06 (+26.27%)
Feb 27, 2026
16w ago
Insider Cluster
NEUTRAL ★ 5/10
$275.64 $253.69▼ −7.96%▼ −5.98%$348.06 (+26.27%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (29h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access